Drug intelligence / Profile preview

alnustone

Development stage
Preclinical
Modality
Small Molecules
01

Overview

Alnustone is a naturally occurring diarylheptanoid compound primarily isolated from plants in the Alnus and Curcuma genera, such as Alnus pendula and Curcuma xanthorrhiza. It is being investigated for its potential therapeutic applications in metabolic and reproductive disorders, specifically obesity and polycystic ovary syndrome (PCOS). Mechanistically, alnustone acts by activating the AMP-activated protein kinase (AMPK) signaling pathway in adipose tissue. This activation promotes energy expenditure by stimulating brown adipose tissue (BAT) activity and inducing the browning of white adipose tissue (WAT). Preclinical studies in mouse models have demonstrated that alnustone administration can effectively reduce body weight gain, attenuate adipocyte hypertrophy, improve insulin resistance, and reverse reproductive dysfunctions such as hyperandrogenism and estrous cycle irregularities.

Other names
(E,E)-1,7-diphenyl-1,3-heptadien-5-one(1E,3E)-1,7-diphenylhepta-1,3-dien-5-one
02

Targets

CaM (Calmodulin)TLR4 (Toll-like receptor 4)NF-κBTNFA (Tumor necrosis factor alpha (soluble))IRAK1 (Interleukin-1 receptor-associated kinase 1)

Beyond the preview

Go deeper on alnustone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alnustone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call